Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - allopurinol, quantity: 300 mg - tablet, uncoated - excipient ingredients: powdered cellulose; povidone; macrogol 4000; crospovidone; purified talc; magnesium stearate; microcrystalline cellulose - main clinical manifestations of urate/uric acid deposition. these are gouty arthritis, skin tophi and/or renal involvement through crystal deposition or stone formation. such clinical manifestations may occur in: idiopathic gout; uric acid lithiasis; acute uric acid nephropathy; neoplastic disease and myeloproliferative disease with high cell turnover rates, in which high urate levels occur either spontaneously or after cytotoxic therapy; certain enzyme disorders which lead to overproduction of urate and involve hypoxanthine guanine phosphoribosyltransferase including lesch-nyhan syndrome, glucose-6-phosphatase including glycogen storage disease, phosphoribosylpyrophosphate synthetase, phosphoribosylpyrophosphate amidotransferase. management of 2,8-dihydroxyadenine (2,8-dha) renal stones relate to deficient activity of adenine phosphoribosyl transferase. management of recurrent mixed calcium oxalate renal stones in the presence of hyperuricosuria, when fluid, dietary and similar measures have failed.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - allopurinol, quantity: 100 mg - tablet, uncoated - excipient ingredients: powdered cellulose; povidone; macrogol 4000; crospovidone; purified talc; magnesium stearate; microcrystalline cellulose - main clinical manifestations of urate/uric acid deposition. these are gouty arthritis, skin tophi and/or renal involvement through crystal deposition or stone formation. such clinical manifestations may occur in: idiopathic gout; uric acid lithiasis; acute uric acid nephropathy; neoplastic disease and myeloproliferative disease with high cell turnover rates, in which high urate levels occur either spontaneously or after cytotoxic therapy; certain enzyme disorders which lead to overproduction of urate and involve hypoxanthine guanine phosphoribosyltransferase including lesch-nyhan syndrome, glucose-6-phosphatase including glycogen storage disease, phosphoribosylpyrophosphate synthetase, phosphoribosylpyrophosphate amidotransferase. management of 2,8-dihydroxyadenine (2,8-dha) renal stones relate to deficient activity of adenine phosphoribosyl transferase. management of recurrent mixed calcium oxalate renal stones in the presence of hyperuricosuria, when fluid, dietary and similar measures have failed.

Unió Europea - anglès - EMA (European Medicines Agency)

grunenthal gmbh - allopurinol, lesinurad - gout - antigout preparations - duzallo is indicated in adults for the treatment of hyperuricaemia in gout patients who have not achieved target serum uric acid levels with an adequate dose of allopurinol alone.

Malta - anglès - Malta Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - allopurinol - tablet - allopurinol 100 mg - antigout preparations

Malta - anglès - Malta Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - allopurinol - tablet - allopurinol 300 mg - antigout preparations

Regne Unit - anglès - MHRA (Medicines & Healthcare Products Regulatory Agency)

teva uk ltd - allopurinol - oral tablet - 100mg

Malta - anglès - Malta Medicines Authority

pinewood laboratories limited ballymacarbry, clonmel, co. tipperary, ireland - allopurinol - tablet - allopurinol 300 mg - antigout preparations

Regne Unit - anglès - myHealthbox

milpharm limited - allopurinol - tablets - 100mg - preparations inhibiting uric acid production - it is indicated for reducing urate/uric acid formation in conditions where urate/uric acid deposition has already occurred (e.g. gouty arthritis, skin tophi, nephrolithiasis) or is a predictable clinical risk (e.g. treatment of malignancy potentially leading to acute uric acid nephropathy). the main clinical conditions where urate/uric acid deposition may occur are: idiopathic gout; uric acid lithiasis; acute uric acid nephropathy; neoplastic disease and myeloproliferative disease with high cell turnover rates, in which high urate levels occur either spontaneously, or after cytotoxic therapy; certain enzyme disorders which lead to overproduction of urate, for example: hypoxanthine-guanine phosphoribosyltransferase, including lesch-nyhan syndrome; glucose-6-phosphatase including glycogen storage disease; phosphoribosylpyrophosphate synthetase, phosphoribosylpyrophosphate amidotransferase; adenine phosphoribosyltransferase. allopurinol is indicated for management of 2,8-dihydroxyadenine (2,8-dha) renal stones

Regne Unit - anglès - myHealthbox

milpharm limited - allopurinol - tablets - 300mg - preparations inhibiting uric acid production - it is indicated for reducing urate/uric acid formation in conditions where urate/uric acid deposition has already occurred (e.g. gouty arthritis, skin tophi, nephrolithiasis) or is a predictable clinical risk (e.g. treatment of malignancy potentially leading to acute uric acid nephropathy). the main clinical conditions where urate/uric acid deposition may occur are: idiopathic gout; uric acid lithiasis; acute uric acid nephropathy; neoplastic disease and myeloproliferative disease with high cell turnover rates, in which high urate levels occur either spontaneously, or after cytotoxic therapy; certain enzyme disorders which lead to overproduction of urate, for example: hypoxanthine-guanine phosphoribosyltransferase, including lesch-nyhan syndrome; glucose-6-phosphatase including glycogen storage disease; phosphoribosylpyrophosphate synthetase, phosphoribosylpyrophosphate amidotransferase; adenine phosphoribosyltransferase. allopurinol is indicated for management of 2,8-dihydroxyadenine (2,8-dha) renal stones r

Canadà - anglès - Health Canada

marcan pharmaceuticals inc - allopurinol - tablet - 100mg - allopurinol 100mg - antigout agents